Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02461069
Recruitment Status : Completed
First Posted : June 3, 2015
Last Update Posted : October 11, 2018
Sponsor:
Collaborator:
Biogen
Information provided by (Responsible Party):
University Hospital Muenster

Brief Summary:
This is an exploratory study, which allows analysis of multiple immune parameters derived from peripheral blood mononuclear cells (PBMCs) from patients with relapsing remitting multiple sclerosis before and during immune-modulatory treatment with dimethyl fumarate in comparison to PBMCs from healthy subjects.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis, Relapsing-Remitting Drug: Dimethyl fumarate Phase 4

Detailed Description:
The purpose of the trial is to shed more light on the mechanisms of action of dimethyl fumarate in patients with relapsing remitting multiple sclerosis. More specifically the influence of dimethyl fumarate on peripheral immune cells will be addressed to evaluate changes in cytokine production by the distinct T cell subsets and the differentiation capacity of naïve T cells. Furthermore, the impact of dimethyl fumarate treatment on the migratory capacity of T cells as well as the evaluation of changes in the suppressive capacity of regulatory T cells will be evaluated. To put the obtained results into context, response data of dimethyl fumarate-treated patients will be compared with data from healthy subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)
Actual Study Start Date : May 6, 2015
Actual Primary Completion Date : January 24, 2018
Actual Study Completion Date : May 7, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Dimethyl fumarate treatment arm (A)
All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
Drug: Dimethyl fumarate
Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
Other Name: Tecfidera®

No Intervention: Healthy subject arm (B)
Healthy subjects will not receive any treatment for RRMS during the study.



Primary Outcome Measures :
  1. Expression of lymphocyte phenotypic surface markers in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis. [ Time Frame: 0, 8, 16 and 24 weeks after initiation of investigational treatment (week 0) ]
  2. Expression of lymphocyte phenotypic surface markers in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects. [ Time Frame: 0, 8, 16 and 24 weeks after initiation of investigational treatment (week 0) ]

Secondary Outcome Measures :
  1. T cell effector functions in terms of cytokine production of CD4+ and CD8+ in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis. [ Time Frame: 0, 8, 16 and 24 weeks after initiation of investigational treatment (week 0) ]
  2. T cell effector functions in terms of cytokine production of CD4+ and CD8+ in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects. [ Time Frame: 0, 8, 16 and 24 weeks after initiation of investigational treatment (week 0) ]
  3. Migratory capacity of immune cells (percentage of migrated cells) in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis. [ Time Frame: 0 and 24 weeks after initiation of investigational treatment (week 0) ]
  4. Migratory capacity of immune cells (percentage of migrated cells) in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects. [ Time Frame: 0 and 24 weeks after initiation of investigational treatment (week 0) ]
  5. Mitochondrial energy metabolism of T cells upon dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis. [ Time Frame: 0 and 24 weeks after initiation of investigational treatment (week 0) ]
  6. Mitochondrial energy metabolism of T cells upon dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects. [ Time Frame: 0 and 24 weeks after initiation of investigational treatment (week 0) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy subjects:

  • H-1. Written informed consent must be obtained before any assessment is performed.
  • H-2. Male and female subjects aged 18 - 60 years.
  • H-3. No history of multiple sclerosis or clinically isolated syndrome.
  • H-4. No history of other autoimmune diseases, which has been treated systemically with corticosteroids, immunomodulators or immunosuppressive drugs at any time point.

RRMS patients:

  • MS-1. Written informed consent must be obtained before any assessment is performed.
  • MS-2. Male and female subjects aged 18 - 60 years.
  • MS-3. Patients with RRMS, defined by 2010 revised McDonald criteria.
  • MS-4. Patients with an Expanded Disability Status Scale (EDSS) score of 0-6.0.
  • MS-5. Patients with one of the following treatment status:

    • Naïve to disease modifying (DM) treatment (i.e. no DM treatment for at least 1 month),
    • Currently on MS therapy with interferon β-1 or glatiramer acetate and willing to switch to dimethyl fumarate (Tecfidera®).
  • MS-6. MRI-scan of the brain ≤ 3 months at screening.

Exclusion Criteria:

RRMS patients:

  • MS-1. Known hypersensitivity to dimethyl fumarate or any ingredients of Tecfidera® (microcrystalline cellulose; croscarmellose-sodium; talcum; high dispersion, hydrophobic silicon dioxide; magnesiumstearate (Ph. Eur.); triethylcitrate; methacrylic acid-methacrylate copolymer (1:1) (Ph. Eur.); methacrylic acid-ethylacrylate copolymer (1:1)-dispersion 30% (Ph. Eur.), simeticon, sodiumdodecylsulfate, polysorbate 80, gelantine, titanium oxide (E171), brilliant blue (E133), hydrated Iron(III)-oxide hydroxide (E172), shellac, potassium hydroxide.
  • MS-2. A MS-relapse within 30 days prior to screening.
  • MS-3. Known history of active tuberculosis or active tuberculosis determined by a positive QuantiFERON® TB Gold test (i.e. a negative test result has to be provided at screening unless a negative test result exists from the last 3 months prior to screening).
  • MS-4. Moderate to severe impairment of liver function or persisting elevations > 2 x ULN (confirmed by retest) of serum glutamic pyruvic transaminase/ alanine aminotransferase (SGPT/ALT) or serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST), except patients with confirmed Gilbert´s syndrome (Meulengracht´s disease).
  • MS-5. Moderate to severe impairment of renal function, as shown by serum creatinine > 133 μmol/L (or > 1.5 mg/dL).
  • MS-6. Patients with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia.
  • MS-7. Women of childbearing potential not utilizing highly effective contraception.

Both populations:

  • MS/H-1. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
  • MS/H-2. Subjects unlikely to comply with protocol as determined by investigator, e.g., uncooperative attitude, inability to return for follow-up visits (e.g. major physical disability), and known unlikelihood of completing the study.
  • MS/H-3. Clinically relevant cardiovascular, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the subject at risk by participating in the study.
  • MS/H-4. Subjects with ulcerative colitis or Crohn´s disease.
  • MS/H-5. Subjects with a congenital or acquired severe immunodeficiency, a history of cancer (except for basal or squamous cell skin lesions which have been surgically excised, with no evidence of metastasis), lymph proliferative disease, or any subject who has received lymphoid irradiation.
  • MS/H-6. Human immunodeficiency virus (HIV) positive, hepatitis B virus positive or hepatitis C virus positive subjects (i.e. a negative test result has to be provided at screening. In the presence of a negative test result from the last 3 months prior to screening, the test has not to be repeated at screening.).
  • MS/H-7. Acute or chronic infection.
  • MS/H-8. History of drug or alcohol abuse.
  • MS/H-9. Use of adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 4 weeks prior to screening.
  • MS/H-10. Prior or concomitant use of cytokine therapy or intravenous immunoglobulins in the 3 months prior to screening.
  • MS/H-11. Prior use of alemtuzumab or cladribine.
  • MS/H-12. Prior use (within 1 year) of fingolimod (Gilenya®) or natalizumab (Tysabri®).
  • MS/H-13. Prior use (within 2 years) of mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporine, methotrexate or mycophenolate mofetil.
  • MS/H-14. Prior treatment with teriflunomide or leflunomide, unless successful wash-out, confirmed by plasma concentration of < 0.02 μg/ml.
  • MS/H-15. Prior use of any investigational drug in the 6 months preceding screening.
  • MS/H-16. Pregnant or breast-feeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02461069


Locations
Layout table for location information
Germany
Neurologisches Studienzentrum Dr. Schmidt/Dr. Neudecker/ Dr. Viehbahn/Dr. Kronenberger
Bonn, Germany, 53111
Neurologische Gemeinschaftspraxis im Bienenkorbhaus
Frankfurt am Main, Germany, 60313
Neurologische Univ.-Klinik
Heidelberg, Germany, 69120
Klinik und Poliklinik für Neurologie, Universitätsklinikum Mainz
Mainz, Germany, 55131
University Hospital Muenster, Department of Neurology
Muenster, Germany, 48149
MVZ-Neurologie Klinikum Osnabrück GmbH
Osnabrück, Germany, 49076
Sponsors and Collaborators
University Hospital Muenster
Biogen
Investigators
Layout table for investigator information
Principal Investigator: Luisa Klotz, Prof. Dr. University Hospital Muenster
Layout table for additonal information
Responsible Party: University Hospital Muenster
ClinicalTrials.gov Identifier: NCT02461069    
Other Study ID Numbers: DIMAT-MS
2014-003481-25 ( EudraCT Number )
U1111-1164-2476 ( Other Identifier: Universal Trial Number )
First Posted: June 3, 2015    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: October 2018
Keywords provided by University Hospital Muenster:
dimethyl fumarate
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Dimethyl Fumarate
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs